F.M. MacKenzie, C.A. Miller, I.M. Gould

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

Serotypes, genotypes and antimicrobial resistance patterns of human diarrhoeagenic Escherichia coli isolates circulating in southeastern China Y. Chen,

Laboratory diagnosis and biosafety issues of biological warfare agents

Interpretive criteria of ceftibuten disk diffusion susceptibility tests according to the DIN method Kleinkauf N. , Rodloff A.C. Clinical Microbiology.

Bloodstream infections among carriers of carbapenem-resistant Klebsiella pneumoniae: etiology, incidence and predictors S. Amit, H. Mishali, T. Kotlovsky,

R. Cantón, A. Novais, A. Valverde, E. Machado, L. Peixe, F. Baquero, T

Defining an extended-spectrum β-lactamase

Approach to diagnosis of infective endocarditis

Herpes zoster in non-hospitalized children

Evolution of extended-spectrum β-lactamases by mutation

Defining an extended-spectrum β-lactamase

In vitro effects of cefotaxime and ceftriaxone on Salmonella typhi within human monocyte-derived macrophages B. Ekinci, A.Y. Coban, A. Birinci, B. Durupinar,

Evaluation of VITEK 2 for analysis of Enterobacteriaceae using the Advanced Expert System (AES) versus interpretive susceptibility guidelines used at.

L. Poirel, P. Nordmann Clinical Microbiology and Infection

Extended-spectrum β-lactamase/AmpC- and carbapenemase-producing Enterobacteriaceae in animals: a threat for humans? J.-Y. Madec, M. Haenni, P. Nordmann,

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

Is the prevalence of antibiotic-resistant organisms changing in Canadian hospitals? Comparison of point-prevalence survey results in 2010 and 2012 V.

Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia.

W. Witte, B. Pasemann, C. Cuny Clinical Microbiology and Infection

How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach D. Guillemot Clinical Microbiology.

Rapid detection of enterobacteriaceae producing extended spectrum beta-lactamases directly from positive blood cultures by matrix-assisted laser desorption.

Vector control: a cornerstone in the malaria elimination campaign

Evaluation of a diagnostic flow chart for detection and confirmation of extended spectrum β-lactamases (ESBL) in Enterobacteriaceae S. Polsfuss, G.V.

Phenotypic detection of extended-spectrum β-lactamase production in Enterobacteriaceae: review and bench guide L. Drieux, F. Brossier, W. Sougakoff,

Changes in Escherichia coli resistance patterns during and after antibiotic therapy: a longitudinal study among outpatients in Germany E. Raum, S. Lietzau,

Multicenter study of the in vitro activity of cefepime in comparison with five other broad- spectrum antibiotics against clinical isolates of Gram-positive.

Training for the infectious diseases speciality in Norway

L.-T. Wu, S.-W. Hung, Y.-C. Chuang, H.-E. Chen, R.N. Jones, W.-L. Yu

Prevalence of extended-spectrum β-lactamases in isolates of the Enterobacter cloacae complex from German hospitals H. Hoffmann, E. Stürenburg, J. Heesemann,

Laboratory diagnosis and biosafety issues of biological warfare agents

In vitro selective concentrations of cefepime and ceftazidime for AmpC β-lactamase hyperproducer Enterobacter cloacae variants Maria-Cristina Negri,

Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin- clavulanate and piperacillin-tazobactam with extended-spectrum.

Development and clinical validation of a molecular diagnostic assay to detect CTX-M- type β-lactamases in Enterobacteriaceae J.D.D. Pitout, N. Hamilton,

Control of infections due to extended-spectrum β-lactamase-producing organisms in hospitals and the community R.E. Warren, G. Harvey, R. Carr, D. Ward,

C. Varela, A. Oliver, T.M. Coque, F. Baquero, R. Canton

A comparative study of the in vitro activity of meropenem and representatives of the major classes of broad-spectrum antibiotics J. Moira Greenhalgh,

S. Bengtsson, C. Bjelkenbrant, G. Kahlmeter

In vitro selection of antibiotic resistance in Pseudomonas aeruginosa

Four-year epidemiological study of extended-spectrum β-lactamase-producing Enterobacteriaceae in a French teaching hospital L. Gibold, F. Robin, R.-N.

Laboratory diagnosis of Clostridium difficile disease

Recent developments in staphylococcal scalded skin syndrome

I. Faria-Ramos, M. J. Espinar, R. Rocha, J. Santos-Antunes, A. G

Long-term study of the frequency of Escherichia coli and Klebsiella pneumoniae isolates producing extended-spectrum β-lactamases L. Romero, L. López,

Highly antibiotic-resistant Acinetobacter baumannii clinical isolates are killed by the green tea polyphenol (–)-epigallocatechin-3-gallate (EGCG) A.

Jacques Sirot Clinical Microbiology and Infection

Activity of cefepime and carbapenems in experimental pneumonia caused by porin- deficient Klebsiella pneumoniae producing FOX-5 β-lactamase C. Pichardo,

Colonization of residents and staff of a long-term-care facility and adjacent acute-care hospital geriatric unit by multiresistant bacteria A. March,

Definition of the Clinical Antibacterial Spectrum of Activity

Clinical infection services—the Leiden experience

Ethan Rubinstein, Itzhak Levy Clinical Microbiology and Infection

R. Cantón, A. Novais, A. Valverde, E. Machado, L. Peixe, F. Baquero, T

Transferable plasmid mediating resistance to multiple antimicrobial agents in Klebsiella pneumoniae isolates in Greece I. Galani, E. Xirouchaki, K. Kanellakopoulou,

Clinical Microbiology and Infection

Clinical Microbiology and Infection

W. Eugene Sanders, Christine C. Sanders

Overview of cefixime use in community-acquired infections

Evaluation of the CLSI cefoxitin 30-µg disk-diffusion method for detecting methicillin resistance in staphylococci L.-X. Zhu, Z.-W. Zhang, C. Wang, H.-W.

The in vitro activity of moxifloxacin against Haemophilus influenzae and Moraxella catarrhalis explored using a pharmacodynamic model Alasdair P. MacGowan,

Facilitating learning and change in physicians: Implications for a system of continuing medical education in Europe Robert D. Fox Clinical Microbiology.

Abstracts Clinical Microbiology and Infection

New oral cephalosporins in pediatric community-acquired infections

Carratalà J. Clinical Microbiology and Infection

J.L. Balcázar Clinical Microbiology and Infection

G.C. Schito Clinical Microbiology and Infection

New patterns of HIV-1 resistance during HAART

G. Kahlmeter Clinical Microbiology and Infection

Impact of antibiotic restrictions: the patient's perspective

The future of diagnostic bacteriology

Multi-centre evaluation of a phenotypic extended spectrum β-lactamase detection guideline in the routine setting T.N. Platteel, J.W. Cohen Stuart, A.J.

Serotypes, genotypes and antimicrobial resistance patterns of human diarrhoeagenic Escherichia coli isolates circulating in southeastern China Y. Chen,

Presentation transcript:

Comparison of screening methods for TEM- and SHV-derived extended-spectrum β- lactamase detection F.M. MacKenzie, C.A. Miller, I.M. Gould Clinical Microbiology and Infection Volume 8, Issue 11, Pages 715-724 (November 2002) DOI: 10.1046/j.1469-0691.2002.00473.x Copyright © 2002 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 1 Standard NCCLS disk diffusion testing: % ESBL producers (n = 22) which were categorized as resistant to specified antibiotics by standard NCCLS breakpoints. FAM, cefamandole; CTT, cefotetan; FOX, cefoxitin; CXM, cefuroxime; CFM, cefixime; CFP, cefoperazone; CTX, cefotaxime; CPD, cefpodoxime; SUL, cefsulodin; CAZ, ceftazidime; CTB, ceftibuten; ZOX, ceftizoxime; CRO, ceftriaxone; MOX, moxalactam; FEP, cefepime; PIR, cefpirome; ATM, aztreonam. Clinical Microbiology and Infection 2002 8, 715-724DOI: (10.1046/j.1469-0691.2002.00473.x) Copyright © 2002 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 2 Jarlier test method: % sensitivity and specificity of Jarlier test detailed for each antibiotic tested (three ESBL negative, and 22 ESBL positive). FAM, cefamandole; CTT, cefotetan; FOX, cefoxitin; CXM, cefuroxime; CFM, cefixime; CFP, cefoperazone; CTX, cefotaxime; CPD, cefpodoxime; SUL, cefsulodin; CAZ, ceftazidime; CTB, ceftibuten; ZOX, ceftizoxime; CRO, ceftriaxone; MOX, moxalactam; FEP, cefepime; PIR, cefpirome; ATM, aztreonam. Clinical Microbiology and Infection 2002 8, 715-724DOI: (10.1046/j.1469-0691.2002.00473.x) Copyright © 2002 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 3 Disk-on-disk test: % sensitivity and specificity of the disk-on-disk test detailed for each antibiotic tested (three ESBL positive, and 22 ESBL negative). FAM, cefamandole; CTT, cefotetan; FOX, cefoxitin; CXM, cefuroxime; CFM, cefixime; CFP, cefoperazone; CTX, cefotaxime; CPD, cefpodoxime; SUL, cefsulodin; CAZ, ceftazidime; CTB, ceftibuten; ZOX, ceftizoxime; CRO, ceftriaxone; MOX, moxalactam; FEP, cefepime; PIR, cefpirome; ATM, aztreonam. Clinical Microbiology and Infection 2002 8, 715-724DOI: (10.1046/j.1469-0691.2002.00473.x) Copyright © 2002 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 4 Modified three-dimensional testing: % sensitivity and specificity of the modified three-dimensional test detailed for each antibiotic tested (three ESBL negative, and 22 ESBL positive). FAM, cefamandole; CTT, cefotetan; FOX, cefoxitin; CXM, cefuroxime; CFM, cefixime; CFP, cefoperazone; CTX, cefotaxime; CPD, cefpodoxime; SUL, cefsulodin; CAZ, ceftazidime; CTB, ceftibuten; ZOX, ceftizoxime; CRO, ceftriaxone; MOX, moxalactam; FEP, cefepime; PIR, cefpirome; ATM, aztreonam. Clinical Microbiology and Infection 2002 8, 715-724DOI: (10.1046/j.1469-0691.2002.00473.x) Copyright © 2002 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 5 (a) E test—intrinsic activity/extrapolation of curve to read MIC. (b) E test—paradoxical effect. Clinical Microbiology and Infection 2002 8, 715-724DOI: (10.1046/j.1469-0691.2002.00473.x) Copyright © 2002 European Society of Clinical Infectious Diseases Terms and Conditions